In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of He... (hreatening and minor bleeding as well as...)

HOME >> MEDICINE >> NEWS

In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack

Date:11/4/2007

hreatening and minor bleeding as well as the overall safety and tolerability of prasugrel.

Patients were randomly assigned to one of two treatment groups and given a loading dose of either prasugrel 60 mg or the approved loading dose of clopidogrel 300 mg anytime between randomization and one hour after the completion of the PCI procedure, followed by a daily maintenance dose of either prasugrel 10 mg or clopidogrel 75 mg. All patients also received a daily low dose of aspirin.

Antiplatelet agents are critical for both acute and maintenance therapy to inhibit platelet activation and subsequent aggregation that occur in diseased arteries and as adjunct therapy to invasive procedures such as percutaneous coronary intervention.

About prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndrome undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke.

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Kolkata: Landmark Health City on the Cards
3. Heart Center at Sinai Conducts Landmark Study on Aspirin Resistance
4. Scientists Map Key Landmarks in Human Genome
5. Landmark Study Prompts Rethink of Genetic Code
6. FDA approves Phase 0 trial which tests experimental drugs on humans
7. SARS-Free Taiwan to Mark End Phase of Global Fight
8. S. Africa AIDS in death phase
9. Spray on contraceptive clears Phase I trial
10. Phase 3 trials of two multi-kinase inhibitors against cancer
11. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine

Post Your Comments:

In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of He...(hreatening and minor bleeding as well as...),Health